Related Experiment Video
Updated: May 7, 2026
05:34
Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders
Published on: August 18, 2023
4.0K
β-Blockers and chronic obstructive pulmonary disease: inappropriate avoidance?
Deborah S Minor1, Allison M Meyer, R C Long
1Department of Medicine, University of Mississippi Medical Center, Jackson, MS.
Journal of Clinical Hypertension (Greenwich, Conn.)
|October 10, 2013
Summary
Beta-blockers (BBs) are safe and beneficial for patients with chronic obstructive pulmonary disease (COPD), despite concerns about bronchoconstriction. Adhering to guidelines for BB use can reduce mortality and morbidity in COPD patients.
Area of Science:
- Pulmonology and Cardiology
- Pharmacotherapy
Background:
- Chronic obstructive pulmonary disease (COPD) is a leading cause of death, frequently co-occurring with cardiovascular conditions.
- Clinicians hesitate to prescribe beta-blockers (BBs) for COPD patients due to bronchoconstriction fears, despite evidence of tolerability.
- COPD treatments can exacerbate cardiovascular disease (CVD) events.
Purpose of the Study:
- To evaluate the role and safety of beta-blocker (BB) use in patients with chronic obstructive pulmonary disease (COPD).
- To address clinical reluctance in prescribing BBs for COPD patients despite existing evidence and guidelines.
- To highlight potential benefits of BB adherence for reducing morbidity and mortality in COPD.
Main Methods:
- Review of current treatment guidelines for COPD and cardiovascular disease management.
- Analysis of existing evidence regarding beta-blocker (BB) tolerability and efficacy in COPD patients.
- Assessment of the impact of guideline adherence on patient outcomes.
Main Results:
- Evidence suggests beta-blockers (BBs) are generally well-tolerated in patients with COPD, even severe cases.
- Treatment guidelines support BB use for cardiovascular conditions in COPD patients.
- Adherence to guidelines for BB prescription could significantly decrease morbidity and mortality.
Conclusions:
- Beta-blockers (BBs) should be considered for cardiovascular management in patients with COPD, aligning with current guidelines.
- Overcoming reluctance to prescribe BBs can improve outcomes for COPD patients with comorbid cardiovascular conditions.
- Further research is needed to refine therapeutic strategies for managing COPD patients with cardiovascular disease.
More Related Videos
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
01:24Chronic Obstructive Pulmonary Disease
3.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.2K
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
77
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
77
01:22Heart Failure Drugs: β-Blockers
3.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
3.0K